Key Highlights
- OXB launched a fast-track viral vector service on 13 April 2026, compressing AAV manufacturing timelines from roughly 15 months to as little as seven, and lentiviral from 12-18 months to around nine.
- FY2025 results (26 March 2026) showed revenue of £170.9m (up 33% constant currency) and operating EBITDA of £8.1m — the company's first full year of operating profitability, swinging from a £15.3m loss.
- Year-end cash stood at £96.9m, up from £60.7m, with net cash of £55.4m and a revenue backlog up about 36% to roughly £204m.
- A March 2026 licensing deal granted Australia's Viral Vector Manufacturing Facility a worldwide, non-exclusive licence to the inAAVate platform, monetising the technology beyond in-house manufacturing.
- Management guided FY2026 revenue of £220m-£240m at constant currency (around 60% already contracted) and an operating EBITDA margin of roughly 10%, weighted to the second half.
- Longer-term targets include 25%-30% revenue growth in each of 2027 and 2028, a margin above 20% in 2027, and one approaching 30% within five to six years.
Tackling Gene Therapy's Toughest Bottleneck
Oxford Biomedica has moved to sharpen its commercial edge in one of biotechnology's most stubborn bottlenecks: getting a gene therapy from the laboratory bench into a compliant manufacturing suite. On 13 April 2026 the Oxford-based contract developer and manufacturer unveiled a fast-track viral vector offering that, on the company's own figures, compresses the pathway to GMP-grade manufacture for adeno-associated virus (AAV) vectors from an industry norm of roughly 15 months to as little as seven, with lentiviral programmes shortened from the customary 12 to 18 months to around nine.
The launch matters because manufacturing speed has become a currency of its own for cash-constrained biotechs racing to reach clinical milestones before their funding runs dry. For OXB, a company that has spent the past three years remaking itself into a pure-play viral vector specialist, the offering is a bid to convert that structural demand into a wider, faster-cycling order book.
From University Spin-Out to Pure-Play CDMO
Oxford Biomedica is a viral vector contract development and manufacturing organisation (CDMO) serving the cell and gene therapy sector. The group's lineage runs back to a University of Oxford spin-out, and it built early credibility as the manufacturer of the lentiviral vector behind Novartis's CAR-T therapy Kymriah. In recent years management has deliberately exited proprietary drug development to focus on being a services provider, positioning the company as an arms dealer to the gene-therapy industry rather than a competitor to its own clients.
The business now spans two proprietary platforms, the inAAVate AAV system and the LentiVector lentiviral platform, and operates across sites in Oxford in the UK and the Boston and Bedford area of Massachusetts, supplemented by a recently acquired facility in Durham in the United States. That transatlantic footprint underpins its pitch to both European and American developers.
Bundling Platforms Into an Expedited Service
The new offering bundles OXB's plug-and-play process platforms, accumulated platform datasets, advanced analytics and integrated design-to-fill-finish workflow into an expedited service aimed at biotechs facing timeline or financing pressure. The company frames the AAV acceleration as up to a 50% reduction against the industry standard, with the lentiviral route similarly shortened.
Sébastien Ribault, OXB's chief business officer, said viral vector development and manufacture 'represents a frequent bottleneck to clinical readiness', positioning the service as a way to cut standard timelines by up to half. The move follows a March 2026 licensing agreement under which OXB granted Australia's Viral Vector Manufacturing Facility a worldwide, non-exclusive licence to its inAAVate platform, with the LentiVector platform available as an option, for a low single-digit million-dollar upfront fee over a five-year term. Together the two announcements point to a broader strategy of monetising the platforms through multiple channels, not just in-house manufacturing capacity.
A Materially Improved Set of Full-Year Numbers
The commercial push comes off the back of a materially improved set of full-year numbers. In results published on 26 March 2026, OXB reported revenue of £170.9m on a constant-currency basis, up 33% on the prior year, or £168.7m and 31% on a reported basis. More significantly, the company reported operating EBITDA of £8.1m, a swing into profit from a £15.3m loss in 2024, which management described as its first full year of operating profitability.
The balance sheet also strengthened. Year-end cash stood at £96.9m, up from £60.7m, with net cash of £55.4m against £20.6m a year earlier. The revenue backlog grew about 36% to roughly £204m, a figure the company leans on as evidence of forward visibility. That cash improvement was helped by financing secured during 2025, including a $125m loan facility from Oaktree and a £60m equity placement to fund US expansion.
At the half-year stage in 2025 OXB had reported revenue of £73.2m, up 44% year on year, with the operating EBITDA loss narrowing to £8.3m from £20.3m and cash consumption collapsing to £4.8m from £48.6m. The full-year swing to an £8.1m EBITDA profit therefore reflects a genuine second-half inflection rather than a one-off — a move from cash-hungry restructuring to a business that can, for the first time, broadly fund itself from operations.
Guidance, Growth Targets and Competitive Position
Management guided to FY2026 revenue of £220m to £240m at constant currency, with around 60% already covered by contracted orders and coverage rising above 80% once the risk-adjusted pipeline is included. It also guided to an operating EBITDA margin of roughly 10% for 2026, weighted to the second half because final major technology-transfer costs fall in the first six months. Beyond that, the company reiterated targets of 25% to 30% revenue growth in each of 2027 and 2028, a margin above 20% in 2027 and one approaching 30% within five to six years.
OXB operates in a cell and gene therapy market that industry estimates put on a compound annual growth rate of around 18% through 2031, a structural tailwind that has nonetheless attracted well-capitalised rivals. The company competes against dedicated viral vector houses and the gene-therapy arms of larger CDMOs, and speed-to-clinic is emerging as a genuine point of differentiation as clients weigh cost, capacity and regulatory track record.
Where the Risks Sit
Several caveats temper the story. The FY2026 guidance embeds first-half EBITDA losses tied to technology-transfer spending, so the profit picture is back-end loaded and dependent on execution. Revenue remains concentrated among a relatively small number of large clients, leaving the group exposed to order deferrals or programme cancellations in a biotech funding environment that has been uneven. The gene-therapy field itself carries clinical and regulatory risk that flows through to demand for vectors. Sentiment hasn't been uniformly positive either: analysts at JPMorgan are reported to have cut their price target sharply during 2026, underlining that the market wants to see guidance delivered, not merely reaffirmed.
Outlook
Oxford Biomedica enters the second half of 2026 as a company that has, on its own numbers, cleared the hardest part of its turnaround: reaching operating profitability while keeping cash intact. The fast-track service is a logical extension of that progress, aimed squarely at where clients feel the most pain. Yet the valuation implied by reiterated guidance leaves little room for slippage, and the first-half loss profile means the proof will come in the second half. The investment case now hinges less on whether OXB can grow and more on whether it can convert a healthy backlog and a widening set of commercial channels into the margins management has promised.






Please wait processing your request...